Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleBEHAVIORAL PHARMACOLOGY

Galanin Acts at GalR1 Receptors in Spinal Antinociception: Synergy with Morphine and AP-5

Xiao-Ying Hua, Carol S. Hayes, Anthony Hofer, Bethany Fitzsimmons, Kalle Kilk, Ülo Langel, Tamas Bartfai and Tony L. Yaksh
Journal of Pharmacology and Experimental Therapeutics February 2004, 308 (2) 574-582; DOI: https://doi.org/10.1124/jpet.103.058289
Xiao-Ying Hua
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carol S. Hayes
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anthony Hofer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bethany Fitzsimmons
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kalle Kilk
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ülo Langel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tamas Bartfai
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tony L. Yaksh
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The neuropeptide galanin (Gal) and its receptors (GalR1, GalR2, and GalR3) are expressed in spinal cord. We have characterized the pharmacology of the antinociceptive effects of intrathecally (i.t.) administered galanin and its analogs in the formalin test in rats, using an automated flinch detection system. Intrathecal injection of rat galanin (Gal1–29) or human galanin (Gal1–30) produced a dose-dependent inhibition of formalin-evoked flinching in phase 2, but not in phase 1. Relative potency of galanin homologs is Gal1–29 ≥ Gal1–30 > galanin-like peptide1–24 ≥ Gal2–11 = Gal 3–29 (an inactive analog). Galanin1–29 and Gal1–30 are both high-affinity agonists to GalR1/R2, whereas Gal2–11 is a GalR2 receptor agonist. Our data suggest that i.t. galanin-produced antinociception is mediated by activation of GalR1 receptors. When comparing antinociceptive effects of i.t. Gal1–29 to morphine and to 2-amino-5-phosphonopentanoic acid (AP-5, an N-methyl-d-aspartate antagonist), Gal1–29 is of intermediate potency between these two analgesic agents based on the ED50 values. An isobolographic analysis showed synergy between Gal1–29 and morphine and between Gal1–29 and AP-5 on the second phase. Fixed ratio dose combinations of morphine and Gal1–29, or AP-5 and Gal1–29 produced significantly greater antinociception than predicted from simple additivity. In summary, the present findings reveal that 1) spinal galanin produces a reliable inhibition of formalin-induced facilitated nociceptive processing, an effect possibly mediated by GalR1 receptors; and 2) galanin potentiates i.t. morphine and AP-5-induced antinociception.

Footnotes

  • This work was supported by National Institute on Neurological Disorder and Stroke (NS41954).

  • DOI: 10.1124/jpet.103.058289.

  • ABBREVIATIONS: DRG, dorsal root ganglia; Gal, galanin; GalR, galanin receptor; GALP, galanin-like peptide; AP-5, 2-amino-5-phosphonopentanoic acid; ANOVA, analysis of variance; C.I., confidence interval; NMDA, N-methyl-d-aspartate; SP, substance P.

  • ↵1 Current address: Department of Neurochemistry and Neurotoxicology, University of Stockholm, SE-106 91, Stockholm, Sweden.

    • Received August 7, 2003.
    • Accepted November 4, 2003.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 308 (2)
Journal of Pharmacology and Experimental Therapeutics
Vol. 308, Issue 2
1 Feb 2004
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Galanin Acts at GalR1 Receptors in Spinal Antinociception: Synergy with Morphine and AP-5
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleBEHAVIORAL PHARMACOLOGY

Galanin Acts at GalR1 Receptors in Spinal Antinociception: Synergy with Morphine and AP-5

Xiao-Ying Hua, Carol S. Hayes, Anthony Hofer, Bethany Fitzsimmons, Kalle Kilk, Ülo Langel, Tamas Bartfai and Tony L. Yaksh
Journal of Pharmacology and Experimental Therapeutics February 1, 2004, 308 (2) 574-582; DOI: https://doi.org/10.1124/jpet.103.058289

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleBEHAVIORAL PHARMACOLOGY

Galanin Acts at GalR1 Receptors in Spinal Antinociception: Synergy with Morphine and AP-5

Xiao-Ying Hua, Carol S. Hayes, Anthony Hofer, Bethany Fitzsimmons, Kalle Kilk, Ülo Langel, Tamas Bartfai and Tony L. Yaksh
Journal of Pharmacology and Experimental Therapeutics February 1, 2004, 308 (2) 574-582; DOI: https://doi.org/10.1124/jpet.103.058289
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Daily methocinnamox on fentanyl self-administration
  • Abuse potential of botanical cannabidiol
  • Efficacy as a determinant of hyperlocomotion by MOR ligands
Show more Behavioral Pharmacology

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics